Susceptibility to focal and global brain ischemia of alzheimer mice displaying Aβ deposits: Effect of immunoglobulin

Aging and Disease

Volumn 5, Issue 2, 2014, Pages 76-87

  Heikkinen, Riikka ^a   Malm, Tarja ^a   Heikkilä, Janne ^b   Muona, Anu ^c   Tanila, Heikki ^a,b   Koistinaho, Milla ^c   Koistinaho, Jari ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c Medeia Therapeutics Ltd   (Finland)

Author keywords

Alzheimer's disease; ApdE9 mice; Global ischemia; Hippocampus; IVIG treatment

Indexed keywords

MUS;

EID: 84907178382     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14336/AD.2014.050076     Document Type: Article

References (52)

1. Selkoe DJ, American College of Physicians, American Physiological Society (2004). Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med, 140:627-638.
2. Schmidt R, Schmidt H, Fazekas F (2000). Vascular risk factors in dementia. J Neurol, 247:81-87.
3. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997). Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA, 277:813-817.
4. de la Torre JC (2000). Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann N Y Acad Sci, 924:136-152.
5. Koistinaho M, Koistinaho J (2005). Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation. Brain Res Brain Res Rev, 48:240-250.
6. Wendell CR, Waldstein SR, Ferrucci L, O'Brien RJ, Strait JB, Zonderman AB (2012). Carotid atherosclerosis and prospective risk of dementia. Stroke, 43:3319-3324.
7. Chi NF, Chien LN, Ku HL, Hu CJ, Chiou HY (2013). Alzheimer disease and risk of stroke: a population-based cohort study. Neurology, 80:705-711.
8. Cardenas VA, Reed B, Chao LL, Chui H, Sanossian N, DeCarli CC, et al (2012). Associations among vascular risk factors, carotid atherosclerosis, and cortical volume and thickness in older adults. Stroke, 43:2865-2870.
9. Iadecola C (2013). The pathobiology of vascular dementia. Neuron, 80:844-866.
10. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A (1995). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology, 45:461-466.
11. Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C (1997). Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci, 17:7655-7661.
12. Koistinaho M, Kettunen MI, Goldsteins G, Keinanen R, Salminen A, Ort M, et al (2002). Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A, 99:1610-1615.
13. Niwa K, Carlson GA, Iadecola C (2000). Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab, 20:1659-1668.
14. Park L, Anrather J, Forster C, Kazama K, Carlson GA, Iadecola C (2004). Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab, 24:334-342.
15. Park L, Wang G, Zhou P, Zhou J, Pitstick R, Previti ML, et al (2011). Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A, 108:5063-5068.
16. Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH (2004). Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol, 165:357-371.
17. Yam PS, Patterson J, Graham DI, Takasago T, Dewar D, McCulloch J (1998). Topographical and quantitative assessment of white matter injury following a focal ischaemic lesion in the rat brain. Brain Res Brain Res Protoc, 2:315-322.
18. Malm TM, Iivonen H, Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Kanninen K, et al (2007). Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci, 27:3712-3721.
19. Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, Goldsteins G, et al (2008). Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem, 105:584-594.
20. Kanninen K, Malm TM, Jyrkkanen HK, Goldsteins G, Keksa-Goldsteine V, Tanila H, et al (2008). Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci, 39:302-313.
21. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al (2004). Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet, 13:159-170.
22. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y (1997). 'Green mice' as a source of ubiquitous green cells. FEBS Lett, 407:313-319.
23. Malm TM, Koistinaho M, Parepalo M, Vatanen T, Ooka A, Karlsson S, et al (2005). Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis, 18:134-142.
24. Kelly S, McCulloch J, Horsburgh K (2001). Minimal ischaemic neuronal damage and HSP70 expression in MF1 strain mice following bilateral common carotid artery occlusion. Brain Res, 914:185-195.
25. Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H (2012). Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation, 9:105-2094-9-105.
26. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al (2010). Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation, 7:90-2094-7-90.
27. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, et al (2002). Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol, 52:253-256.
28. Liu J, Solway K, Messing RO, Sharp FR (1998). Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils. J Neurosci, 18:7768-7778.
29. Mattson MP, Zhu H, Yu J, Kindy MS (2000). Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J Neurosci, 20:1358-1364.
30. Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, et al (2008). Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis, 25:268-278.
31. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, et al (2011). Cerebrovascular lesions induce transient beta-amyloid deposition. Brain, 134:3697-3707.
32. Qi JP, Wu H, Yang Y, Wang DD, Chen YX, Gu YH, et al (2007). Cerebral ischemia and Alzheimer's disease: the expression of amyloid-beta and apolipoprotein E in human hippocampus. J Alzheimers Dis, 12:335-341.
33. Widiapradja A, Vegh V, Lok KZ, Manzanero S, Thundyil J, Gelderblom M, et al (2012). Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. J Neurochem, 122:321-332.
34. Fann DY, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, et al (2013). Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis, 4:e790.
35. Eggen BJ, Raj D, Hanisch UK, Boddeke HW (2013). Microglial phenotype and adaptation. J Neuroimmune Pharmacol, 8:807-823.
36. Hanisch UK, Kettenmann H (2007). Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci, 10:1387-1394.
37. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, et al (2007). Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci, 10:1544-1553.
38. Grammas P, Martinez J, Miller B (2011). Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med, 13:e19.
39. Abuznait AH, Kaddoumi A (2012). Role of ABC transporters in the pathogenesis of Alzheimer's disease. ACS Chem Neurosci, 3:820-831.
40. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, et al (2012). Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain, 135:181-189.
41. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al (2005). P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest, 115:3285-3290.
42. Yu D, Corbett B, Yan Y, Zhang GX, Reinhart P, Cho SJ, et al (2012). Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging, 33:2942-2947.
43. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M (2011). Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem, 286:17536-17542.
44. Banks WA, Kumar VB, Farr SA, Nakaoke R, Robinson SM, Morley JE (2011). Impairments in brain-to-blood transport of amyloid-beta and reabsorption of cerebrospinal fluid in an animal model of Alzheimer's disease are reversed by antisense directed against amyloid-beta protein precursor. J Alzheimers Dis, 23:599-605.
45. Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, et al (2009). ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J Neurosci, 29:5463-5475.
46. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003). Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation, 10:463-470.
47. Lampron A, Lessard M, Rivest S (2012). Effects of myeloablation, peripheral chimerism, and whole-body irradiation on the entry of bone marrow-derived cells into the brain. Cell Transplant, 21:1149-1159.
48. Minogue AM, Jones RS, Kelly RJ, McDonald CL, Connor TJ, Lynch MA (2013). Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice. Neurobiol Aging, S0197-4580(13)00668-4.
49. Karkkainen V, Magga J, Koistinaho J, Malm T (2012). Brain environment and Alzheimer's disease mutations affect the survival, migration and differentiation of neural progenitor cells. Curr Alzheimer Res, 9:1030-1042.
50. Feng R, Rampon C, Tang YP, Shrom D, Jin J, Kyin M, et al (2001). Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron, 32:911-926.
51. Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, et al (2002). Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci, 22:515-522.
52. Ghanbari HA, Ghanbari K, Harris PL, Jones PK, Kubat Z, Castellani RJ, et al (2004). Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell, 3:41-44.